| Letrozole |
ІІ-10085/ 24.06.2010 |
ZEQUIPRA, Film‐coated tablet, 2.5, mg, Pack: 30 |
Ромастру Трейдинг ЕООД, България |
West Pharma Португалия |
39.98 |
8 |
47.98 |
4% |
1.6 |
41.58 |
8.32 |
49.9 |
16% |
6.4 |
47.98 |
9.6 |
57.58 |
|
НСР-1102/04.09.2013 |
19.09.2013 |
Неактивен |
2536 |
| Letrozole |
ІІ-10085/ 24.06.2010 |
ZEQUIPRA, Film‐coated tablet, 2.5, mg, Pack: 30 |
Ромастру Трейдинг ЕООД, България |
West Pharma Португалия |
61.96 |
12.39 |
74.35 |
4% |
2.48 |
64.44 |
12.89 |
77.33 |
16% |
9.91 |
74.35 |
14.87 |
89.22 |
|
КЦРР-445/19.04.2012 |
06.06.2012 |
Неактивен |
2536 |
| Letrozole |
№ ІІ-10085/24.06.2010 |
ZEQUIPRA, Film‐coated tablet, 2.5, mg, Pack: 30 |
Ромастру Трейдинг ЕООД, България |
West Pharma Португалия |
162.54 |
32.51 |
195.05 |
6% |
9.75 |
172.29 |
34.46 |
206.75 |
18% |
29.26 |
201.55 |
40.31 |
241.86 |
|
КЦ-1961/25.01.2011 |
09.02.2011 |
Неактивен |
2536 |
| Stavudine |
EU/1/96/009/008 |
ZERIT, Capsule, hard, 40, mg, Pack: 56 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb, Champ “Lachaud”, La Goualle, 19250 Meymac, France |
217.02 |
43.4 |
260.42 |
4% |
8.68 |
225.7 |
45.14 |
270.84 |
16% |
25 |
250.7 |
50.14 |
300.84 |
цената е заличена с решение КЦРР-1533/25.10.2012 |
КЦРР-687/30.05.2012 |
20.06.2012 |
Заличен |
1226 |
| Stavudine |
EU/1/96/009/006 |
ZERIT, Capsule, hard, 30, mg, Pack: 56 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb, Champ “Lachaud”, La Goualle, 19250 Meymac, France |
210.02 |
42 |
252.02 |
4% |
8.4 |
218.42 |
43.68 |
262.1 |
16% |
25 |
243.42 |
48.68 |
292.1 |
цената е заличена с решение КЦРР-1533/25.10.2012 |
КЦРР-687/30.05.2012 |
20.06.2012 |
Заличен |
1225 |
| Stavudine |
EU/1/96/009/008 |
ZERIT, Capsule, hard, 40, mg, Pack: 56 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb, Champ “Lachaud”, La Goualle, 19250 Meymac, France |
240.88 |
48.18 |
289.06 |
6% |
14.45 |
255.33 |
51.07 |
306.4 |
18% |
30 |
285.33 |
57.07 |
342.4 |
|
КЦ-497/04.02.2009 |
10.03.2009 |
Неактивен |
1226 |
| Stavudine |
EU/1/96/009/006 |
ZERIT, Capsule, hard, 30, mg, Pack: 56 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb, Champ “Lachaud”, La Goualle, 19250 Meymac, France |
233.12 |
46.62 |
279.74 |
6% |
13.99 |
247.11 |
49.42 |
296.53 |
18% |
30 |
277.11 |
55.42 |
332.53 |
|
КЦ-497/04.02.2009 |
10.03.2009 |
Неактивен |
1225 |
| Ibritumomab tiuxetan |
EU/1/03/264/001 |
Zevalin, -, 3.2, mg, Pack: 1 |
Spectrum Pharmaceuticals B.V., Нидерландия |
CIS bio international RN 306-Saclay B.P.32 91192 GIF Sur Yvette Cedex, France |
17651.23 |
3530.25 |
21181.48 |
4% |
10 |
17661.23 |
3532.25 |
21193.48 |
16% |
25 |
17686.23 |
3537.25 |
21223.48 |
|
КЦРР-2944/20.03.2013 |
19.04.2013 |
Неактивен |
2931 |
| Ibritumomab tiuxetan |
EU/1/03/264/001 |
Zevalin, -, 3.2, mg, Pack: 1 |
Bayer Schering Pharma AG,, Германия |
Bayer Schering Pharma AG, Germany |
19429.72 |
3885.94 |
23315.66 |
4% |
10 |
19439.72 |
3887.94 |
23327.66 |
16% |
25 |
19464.72 |
3892.94 |
23357.66 |
|
КЦ-353/19.12.2008 |
05.01.2009 |
Неактивен |
2931 |
| Ibritumomab tiuxetan |
EU/1/03/264/001 |
ZEVALIN, Kit for radiopharmaceutical preparation, 1,6 mg/ml - 2 ml, -, Pack: 1 kit containing: 1 vial of ibritumomab tiuxetan, 1 vial of sodium acetate solution, 1 vial of formulation buffer and 1 empty reaction vial |
Spectrum Pharmaceuticals B.V., Нидерландия |
CIS bio international RN 306-Saclay B.P.32 91192 GIF Sur Yvette Cedex, France |
17335.71 |
3467.14 |
20802.85 |
4% |
10 |
17345.71 |
3469.14 |
20814.85 |
16% |
25 |
17370.71 |
3474.14 |
20844.85 |
корекц.НСР-3921/20.06.2014 |
НСР-3669/06.06.2014 |
04.07.2014 |
Активен |
2931 |
| Solifenacin |
20110053 |
ZEVESIN, Film‐coated tablet, 5, mg, Pack: 30 |
Zentiva k.s., Чешка република |
Zentiva k.s. - Чешка република |
27.11 |
5.42 |
32.53 |
6% |
1.63 |
28.74 |
5.75 |
34.49 |
18% |
4.88 |
33.62 |
6.72 |
40.34 |
|
НСР-2534/24.01.2014 |
19.02.2014 |
Активен |
274 |
| Solifenacin |
№ ІІ - 11791/19.01.2011 |
ZEVESIN, Film‐coated tablet, 5, mg, Pack: 30 |
Zentiva k.s., Чешка република |
Zentiva k.s. - Чешка република |
28.75 |
5.75 |
34.5 |
6% |
1.73 |
30.48 |
6.1 |
36.58 |
18% |
5.18 |
35.66 |
7.13 |
42.79 |
|
КЦРР-2222/06.02.2013 |
03.04.2013 |
Неактивен |
274 |
| Solifenacin |
№ ІІ - 11791/19.01.2011 |
ZEVESIN, Film‐coated tablet, 5, mg, Pack: 30 |
Zentiva k.s., Чешка република |
Zentiva k.s. U Kabelovny 130, 102 37 Prague 10, Чешка Република,Zentiva a.s.Словашка република |
31.29 |
6.26 |
37.55 |
4% |
1.25 |
32.54 |
6.51 |
39.05 |
16% |
5.01 |
37.55 |
7.51 |
45.06 |
|
КЦ-2149/20.04.2011 |
05.05.2011 |
Неактивен |
274 |
| Abacavir |
EU/1/99/112/001-002 |
ZIAGEN, Film‐coated tablet, 300, mg, Pack: 60 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Operations UK Ltd ,Великобритания GlaxoSmithKline Pharmaceuticals S.A. Полша |
347.79 |
69.56 |
417.35 |
4% |
10 |
357.79 |
71.56 |
429.35 |
16% |
25 |
382.79 |
76.56 |
459.35 |
Цената е заличена с решение НСР-2721/06.02.2014 |
КЦ-1824/11.10.2010 |
16.11.2010 |
Заличен |
971 |
| Bemiparin |
20060575 |
ZIBOR, Solution for injection, 2500 IU anti-Xa/0,2 ml, -, Pack: 2 pre-filled syringes |
Menarini International Operations Luxembourg S.A., Люксембург |
Laboratorios Farmaceu-ticos ROVI S.A.,Spain, Rovi Contract Manufacturing S.L., Spain |
5.2 |
1.04 |
6.24 |
7% |
0.36 |
5.56 |
1.11 |
6.67 |
20% |
1.04 |
6.6 |
1.32 |
7.92 |
корекционно решение НСР-6627/09.07.2015 |
НСР-6556/24.06.2015 |
10.07.2015 |
Активен |
3219 |
| Bemiparin |
20060576 |
ZIBOR, Solution for injection, 3500 IU anti-Xa/0,2 ml, -, Pack: 2 pre-filled syringes |
Menarini International Operations Luxembourg S.A., Люксембург |
Laboratorios Farmaceu-ticos ROVI S.A.,Spain, Rovi Contract Manufacturing S.L., Spain |
10.52 |
2.1 |
12.62 |
6% |
0.63 |
11.15 |
2.23 |
13.38 |
18% |
1.89 |
13.04 |
2.61 |
15.65 |
корекционно решение НСР-6629/09.07.2015 |
НСР-6555/24.06.2015 |
10.07.2015 |
Активен |
3220 |
| Bemiparin |
20060575 |
Zibor 2500, Solution for injection, 2500 IU anti-Xa/0.2 ml, IU, Pack: 2 |
Menarini International Operations Luxembourg S.A., Люксембург |
Laboratorios Farmaceu-ticos ROVI S.A.,Spain, Rovi Contract Manufactu-ring, Spain |
6.55 |
1.31 |
7.86 |
7% |
0.46 |
7.01 |
1.4 |
8.41 |
20% |
1.31 |
8.32 |
1.66 |
9.98 |
корекц. Решение НСР-4830/17.10.2014 |
НСР-4741/02.10.2014 |
16.10.2014 |
Неактивен |
3219 |
| Bemiparin |
II-14612/23.10.2006 г. |
Zibor 2500, Solution for injection, 2500 IU anti-Xa/0.2 ml, IU, Pack: 2 |
Menarini International Operations Luxembourg S.A., Люксембург |
Laboratorios Farmaceuticos ROVI S.A.,Spain, Rovi Contract Manufacturing, Spain |
6.59 |
1.32 |
7.91 |
7% |
0.46 |
7.05 |
1.41 |
8.46 |
20% |
1.32 |
8.37 |
1.67 |
10.04 |
|
НСР-637/29.07.2013 |
29.08.2013 |
Неактивен |
3219 |
| Bemiparin |
II-14612/23.10.2006 г. |
Zibor 2500, Solution for injection, 2500 IU anti-Xa/0.2 ml, IU, Pack: 2 |
Menarini International Operations Luxembourg S.A., Люксембург |
Laboratorios Farmaceuticos ROVI S.A.,Spain, Rovi Contract Manufacturing, Spain |
7.18 |
1.44 |
8.62 |
7% |
0.5 |
7.68 |
1.54 |
9.22 |
20% |
1.44 |
9.12 |
1.82 |
10.94 |
промяна на обстоятелства решение КЦPP-232/27.02.2012 |
КЦ-48/21.04.2008 |
23.05.2008 |
Неактивен |
3219 |
| Bemiparin |
20060576 |
Zibor 3500, Solution for injection, 3500 IU anti-Xa/0.2 ml, IU, Pack: 2 |
Menarini International Operations Luxembourg S.A., Люксембург |
Laboratorios Farmaceuti-cos ROVI S.A.,Spain, Rovi Contract Manufactu-ring, Spain |
11.09 |
2.22 |
13.31 |
6% |
0.67 |
11.76 |
2.35 |
14.11 |
18% |
2 |
13.76 |
2.75 |
16.51 |
корекц. Решение НСР-4833/17.10.2014 |
НСР-4740/02.10.2014 |
16.10.2014 |
Неактивен |
3220 |
| Bemiparin |
II-14613/23.10.2006 г. |
Zibor 3500, Solution for injection, 3500 IU anti-Xa/0.2 ml, IU, Pack: 2 |
Menarini International Operations Luxembourg S.A., Люксембург |
Laboratorios Farmaceuticos ROVI S.A.,Spain, Rovi Contract Manufacturing, Spain |
11.11 |
2.22 |
13.33 |
6% |
0.67 |
11.78 |
2.36 |
14.14 |
18% |
2 |
13.78 |
2.76 |
16.54 |
|
НСР-636/29.07.2013 |
29.08.2013 |
Неактивен |
3220 |
| Bemiparin |
II-14613/23.10.2006 г. |
Zibor 3500, Solution for injection, 3500 IU anti-Xa/0.2 ml, IU, Pack: 2 |
Menarini International Operations Luxembourg S.A., Люксембург |
Laboratorios Farmaceuticos ROVI S.A.,Spain, Rovi Contract Manufacturing, Spain |
13.91 |
2.78 |
16.69 |
6% |
0.83 |
14.74 |
2.95 |
17.69 |
18% |
2.5 |
17.24 |
3.45 |
20.69 |
промяна на обстоятелства решение КЦPP-231/27.02.2012 |
КЦ-48/21.04.2008 |
23.05.2008 |
Неактивен |
3220 |
| Risedronate |
5738/09.09.2009 |
ZILAR, Film‐coated tablet, 35, mg, Pack: 4 |
Stada Arzneimittel AG, Германия |
Pharmathen S.A, Гърция; Stada Arzneimittel AG, Германия |
13.69 |
2.74 |
16.43 |
6% |
0.82 |
14.51 |
2.9 |
17.41 |
18% |
2.46 |
16.97 |
3.39 |
20.36 |
Цената е вписана в регистъра на пределните цени с решение НСР-2557/24.01.2014 |
КЦ-1342/01.02.2010 |
22.02.2010 |
Заличен |
890 |
| Cefuroxime |
20030353 |
Zinacef, Powder for solution for injection, 1500, mg, Pack: 1 |
Glaxo Group Ltd., Обединено Кралство |
Glaxo Smith Kline S.p.A.,Italy |
4.81 |
0.96 |
5.77 |
7% |
0.34 |
5.15 |
1.03 |
6.18 |
20% |
0.96 |
6.11 |
1.22 |
7.33 |
Цената се заличава с решение НСР-2362/21.01.2014 |
КЦРР-2784/20.03.2013 |
19.04.2013 |
Заличен |
1790 |
| Cefuroxime |
ІІ-2547/18.07.2008 г |
Zinacef, Powder for solution for injection, 1500, mg, Pack: 1 |
Glaxo Group Ltd., Обединено Кралство |
GlaxoSmithKline S.p.A., Via Alessandro Fleming 2, 37135 Verona, Italy |
4.93 |
0.99 |
5.92 |
7% |
0.35 |
5.28 |
1.06 |
6.34 |
20% |
0.99 |
6.27 |
1.25 |
7.52 |
|
КЦРР-835/15.06.2012 |
02.07.2012 |
Неактивен |
1790 |